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Despite many attempts to prevent surgical site infec-
tions (SSIs), these complications are not uncommon 
in most hospitals while the precise determination of 
the burden of these infections in our country has not 
been performed but crude data in hospitals shows a 
significant cost of managements. With an estimated 
27 million surgical procedures annually, and near 2–
5%  rate  of  SSIs,  approximately  300,000–500,000 
surgical site infections can be predicted to occur each 
year.
1-3 In a study in United States, a mean increase of 
7-10  days  of  postoperative  hospitalization  resulted 
into higher costs, including increase in annual health 
care expenditures ranging from 1–10 billion dollars.
4 
Preoperative  antibiotics  and  aseptic  techniques  are 
most important aspects of care in major surgical proce-
dures but it should be emphasized that all preventive 
measures for surgical site infections are unrealistic due 
to presence of many risk factors that are largely unalter-
able such as comorbid diseases. So the objectives should 
be elimination of all potentially preventable infections 
by the use of evidence based actions. 
The center for disease control (CDC) recommends 
that antibiotic prophylaxis should be used for all clean 
contaminated procedures and some of clean procedures 
such as prosthetic joints or intravascular device inser-
tions.
5 Contaminated procedures and dirty wounds of-
ten do not need any specific antimicrobial prophylaxis 
because this type of wound or procedures have already 
received antibiotic therapy due to presence of an un-
derlying infection. However, if the antibacterial regi-
men  does  not  adequately  cover  all  microorganisms, 
additional prophylaxis regimen should be considered. 
For  example,  when  in  specific  settings,  the  risk  of 
methicilin resistant Staphylococoous (MRSA) is highly 
preventable and the prescribed regimen does not cover 
MRSA, vancomycin may be recommended.  
The benefit of antibiotic prophylaxis in all clean 
procedures  has  not  been determined.  Only  in  some 
invasive  clean  procurers, there  are  recommendation 
about antibiotic use and in minimally invasive ones 
there are few powerful randomized clinical trials and 
the  benefits  of  their  use  should  be  outweighted  by 
potential risks of antibiotic therapy.
6,7      
In this issue of journal, Hatam et al. reported on 
the economic burden of inappropriate antibiotic use 
for  prophylaxis  of  infections  in  surgical  wards  of  
Shiraz University of Medical Sciences affiliated hos-
pitals during year 2004. They found that antibiotics 
were prescribed for 98% procedures in which an anti-
biotic did not have an indication and also the cost for 
a 6 months period of antimicrobial prophylaxis regi-
men was approximately shown 4,623 USD. 
The reported study was completed 7 years ago and 
the research team is to be congratulated on this well 
designed survey. Those who are working in an infec-
tious ward in university hospitals are painfully aware 
of  inappropriate  antibiotic  usage  in  wards  including 
surgical wards and operating rooms. We have a great 
problem  with  these  unnecessary  administrations  and 
need enforcement for reduction of antimicrobial usage. 
The  inappropriate  preoperative  use  of  antibiotics 
may represent a significant portion of the hospital phar-
macy’s expenditure for antibiotics and the surgeons are 
needed to be encouraged to eliminate antibiotics given 
for prophylaxis in inappropriate settings. This goal can 
be reached by educational programs and supervision of 
administration by infectious disease teams. 
However, it seems inappropriate to evaluate antimi-
crobial use based on cost alone. With inappropriate us-
age,  the  over-use  or  under-use,  the  costs  in  terms  of 
mortality, morbidity and resources for fighting against 
developed  resistance  microorganism  or  managing 
wound infections should be  clarified.
8 In these hospitals, 
the exact cost of prophylaxis therapy with consideration 
of above mentioned outcome should be determined. 
Therefore, one needs to know that such a difficulty 
exist  and  cannot  be  determined  simply  by  direct  cost 
analysis methods. Those whose professional activities are Prophylaxis for surgical site infections 
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on health economic policy need to design special research 
projects on all outcomes and direct and indirect costs pro-
duced by inappropriate antibiotic usage in hospitals. 
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